The Real-World Characteristics and Outcomes of Newly Diagnosed Myeloma Patients Ineligible for Clinical Trials

被引：0
|
作者：
Fiala, Mark A. [1 ]
Dukeman, James [1 ]
Stockerl-Goldstein, Keith [1 ]
Tomasson, Michael H. [1 ]
Wildes, Tanya M. [1 ]
Vij, Ravi [1 ]
机构：
[1] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs
    Hari, Parameswaran
    Ung, Brian
    Abouzaid, Safiya
    Agarwal, Amit
    Parikh, Kejal
    [J]. FUTURE ONCOLOGY, 2019, 15 (35) : 4045 - 4056
  • [22] Retrospective Observational Study on Real-World Bortezomib Prescribing Patterns and Outcomes in Newly Diagnosed Multiple Myeloma
    Hoff, Fieke W.
    Banerjee, Rahul
    Khan, Adeel
    McCaughan, Georgia
    Wang, Xiaoliang
    Roose, James
    Larry, D. Anderson, Jr.
    Cowan, Andrew J.
    Rajkumar, Vincent
    Kaur, Gurbakhash
    [J]. BLOOD, 2023, 142
  • [23] Ixazomib Based Maintenance Therapy for the Patients with Newly Diagnosed Multiple Myeloma in Real-World Practice
    Zhong, Liye
    Wei, Yongqiang
    Ping, Baohong
    Li, Xin
    Peng, Hongling
    Li, Yongqain
    Tian, Yuyang
    Liu, Zelin
    Luo, Jun
    Su, Yongzhong
    Chen, Haifei
    He, Yanjuan
    Li, Hongliang
    Wu, Congming
    Sun, Zhiqiang
    Shi, Keqian
    Li, Xiaoliang
    Zhang, Qing
    Hu, Guoyu
    Huang, Gang
    Huang, Zhenqian
    Wang, Weida
    Xia, Zhongjun
    [J]. BLOOD, 2021, 138
  • [24] Bortezomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients: a real-world study of China
    Xu, Jingyu
    Yan, Wenqiang
    Fan, Huishou
    Liu, Jiahui
    Du, Chenxing
    Deng, Shuhui
    Sui, Weiwei
    Xu, Yan
    Qiu, Lugui
    An, Gang
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S159 - S159
  • [25] Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database
    Mian, Hira
    LeBlanc, Richard
    Louzada, Martha
    Masih-Khan, Esther
    McCurdy, Arleigh
    Venner, Christopher P.
    Stakiw, Julie
    Kardjadj, Moustafa
    Jimenez-Zepeda, Victor H.
    Sebag, Michael
    White, Darrell
    Aslam, Muhammad
    Song, Kevin
    Reiman, Anthony
    Kotb, Rami
    Gul, Engin
    Reece, Donna
    [J]. CANCER MEDICINE, 2023, 12 (04): : 4357 - 4362
  • [26] UNDERSTANDING THE REAL-WORLD CLINICAL CHARACTERISTICS OF MULTIPLE MYELOMA PATIENTS IN EUROPE
    Bacon, T.
    Gaudig, M.
    Ito, T.
    Hadfield, A.
    Rider, A.
    [J]. HAEMATOLOGICA, 2017, 102 : 529 - 529
  • [27] Real-World Outcomes for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone, or Bortezomib and Dexamethasone: An Enhanced Electronic Health Records Database Analysis
    Chari, Ajai
    Ung, Brian
    Tian, Marc
    Agarwal, Amit
    Parikh, Kejal
    [J]. BLOOD, 2018, 132
  • [28] Characteristics and treatment pattern comparisons of a real-world cohort of patients eligible and ineligible for moderate-to-severe psoriasis clinical trials
    Wu, J.
    Araujo, A.
    Nordstrom, B.
    Goldblum, O.
    Solotkin, K.
    Lin, C. -Y.
    Johnston, J.
    Kistler, K.
    Fraeman, K.
    Malatestinic, W.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 84 - 84
  • [29] EVALUATION OF OVERALL SURVIVAL ASSOCIATED WITH CHANGE IN DOSING OF BORTEZOMIB, MELPHALAN, AND PREDNISONE REGIMEN IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A REAL-WORLD STUDY
    Mehra, M.
    Potluri, R.
    Lam, A.
    Slavcev, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S113 - S113
  • [30] Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma
    Major, Ajay
    Jakubowiak, Andrzej
    Derman, Benjamin
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (11): : E1000 - E1008
12345